Biophysical identification of natural human antibody targets

天然人类抗体靶标的生物物理鉴定

• 批准号: LP100100392
• 负责人: A/Prof Geoffrey Howlett
• 金额: $ 20.9万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-02-15 至 2013-02-14
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP100100392
• 关键词: Biophysical; identification; natural; human; antibody

A natural human antibody, PAT-SM6, isolated using technology developed by the partner organisation (Patrys), offers promise as a therapy to reduce mortalities due to cancer, the leading cause of death in Australia. The novelty of the approach pioneered by Patrys is the direct production of human antibodies which avoids undesirable side effects associated with the use of antibodies containing non-human components. This project is to discover the specificity of PAT-SM6 for proteins and protein complexes and how these interactions lead to tumour cell death. This work will enhance the effectiveness of human antibody therapies and help in the development of this fast growing area within the biotechnology industry in Australia.

使用合作组织（Patrys）开发的技术分离的天然人类抗体PAT-SM 6，有望作为降低癌症死亡率的疗法，癌症是澳大利亚的主要死因。 Patrys开创的方法的新奇在于直接生产人抗体，避免了与使用含有非人成分的抗体相关的不良副作用。 该项目旨在发现PAT-SM 6对蛋白质和蛋白质复合物的特异性，以及这些相互作用如何导致肿瘤细胞死亡。 这项工作将提高人类抗体疗法的有效性，并有助于澳大利亚生物技术产业中这一快速增长领域的发展。